2 Oct 2023
The phase III clinical trial TUDCA-ALS, trialling the safety and efficacy of tauroursodeoxycholic acid (TUDCA) in ALS, has completed. All clinical trial sites are closing down the double-blind phase activities by the end of September 2023. Data analysis will commence imminently, with top line results expected to be announced by the end of 2023 or beginning of 2024.
More information regarding the announcement of trial results will be published as it becomes available. The open-label extension phase continues at all centres.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 755094.
The TUDCA-ALS consortium would like to thank all participants, carers, clinical staff, and anyone who has expressed interest in the trial.